2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent

TARGET AC Investigators

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives: The aim of this study was to assess the 2-year clinical outcomes of the Firehawk stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel abluminal groove–filled biodegradable-polymer sirolimus-eluting coronary stent, compared with XIENCE (Abbott Vascular, Santa Clara, California), a durable-polymer everolimus-eluting coronary stent. Background: The long-term outcomes of the Firehawk stent have not been evaluated beyond 1 year in a randomized all-comers clinical trial. Methods: The TARGET All Comers study is a prospective, multicenter, all-comers, randomized, noninferiority trial conducted in Europe. A total of 1,653 patients were randomly assigned to undergo implantation of either the Firehawk or the XIENCE stent. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. Results: At 2-year follow-up, the incidence of target lesion failure was 8.7% in the Firehawk group versus 8.6% in the XIENCE group (p = 0.92). The event rates of individual components of the primary endpoint were comparable for the 2 groups. Landmark analyses between 1- and 2-year follow-up revealed no statistically significant difference of TLF for the Firehawk versus the XIENCE stent. Beyond 1 year, very late definite or probable stent thrombosis occurred in 3 patients (0.4%) in the Firehawk group and in 7 patients (0.9%) in the XIENCE group (p = 0.34). Conclusions: The 2-year follow-up of the TARGET All Comers study confirms comparable safety and efficacy profiles of the Firehawk and XIENCE stents.
Original languageEnglish
Pages (from-to)1679-1687
JournalJACC: Cardiovascular Interventions
Volume12
Issue number17
DOIs
Publication statusPublished - 2019

Cite this

@article{d66204678c3a48a0bb76d1f45ad10100,
title = "2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent",
abstract = "Objectives: The aim of this study was to assess the 2-year clinical outcomes of the Firehawk stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel abluminal groove–filled biodegradable-polymer sirolimus-eluting coronary stent, compared with XIENCE (Abbott Vascular, Santa Clara, California), a durable-polymer everolimus-eluting coronary stent. Background: The long-term outcomes of the Firehawk stent have not been evaluated beyond 1 year in a randomized all-comers clinical trial. Methods: The TARGET All Comers study is a prospective, multicenter, all-comers, randomized, noninferiority trial conducted in Europe. A total of 1,653 patients were randomly assigned to undergo implantation of either the Firehawk or the XIENCE stent. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. Results: At 2-year follow-up, the incidence of target lesion failure was 8.7{\%} in the Firehawk group versus 8.6{\%} in the XIENCE group (p = 0.92). The event rates of individual components of the primary endpoint were comparable for the 2 groups. Landmark analyses between 1- and 2-year follow-up revealed no statistically significant difference of TLF for the Firehawk versus the XIENCE stent. Beyond 1 year, very late definite or probable stent thrombosis occurred in 3 patients (0.4{\%}) in the Firehawk group and in 7 patients (0.9{\%}) in the XIENCE group (p = 0.34). Conclusions: The 2-year follow-up of the TARGET All Comers study confirms comparable safety and efficacy profiles of the Firehawk and XIENCE stents.",
author = "{TARGET AC Investigators} and Bo Xu and Yuichi Saito and Andreas Baumbach and Henning Kelb{\ae}k and {van Royen}, Niels and Ming Zheng and Marie-Ang{\`e}le Morel and Paul Knaapen and Ton Slagboom and Johnson, {Thomas W.} and Georgios Vlachojannis and Arkenbout, {Karin E.} and Lene Holmvang and Luc Janssens and Andrzej Ochala and Salvatore Brugaletta and Naber, {Christoph K.} and Richard Anderson and Harald Rittger and Sergio Berti and Emanuele Barbato and Toth, {Gabor G.} and Luc Maillard and Christian Valina and Paweł Buszman and Holge Thiele and Volker Sch{\"a}chinger and Alexandra Lansky and William Wijns",
year = "2019",
doi = "10.1016/j.jcin.2019.05.001",
language = "English",
volume = "12",
pages = "1679--1687",
journal = "JACC Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "17",

}

2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. / TARGET AC Investigators.

In: JACC: Cardiovascular Interventions, Vol. 12, No. 17, 2019, p. 1679-1687.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - 2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent

AU - TARGET AC Investigators

AU - Xu, Bo

AU - Saito, Yuichi

AU - Baumbach, Andreas

AU - Kelbæk, Henning

AU - van Royen, Niels

AU - Zheng, Ming

AU - Morel, Marie-Angèle

AU - Knaapen, Paul

AU - Slagboom, Ton

AU - Johnson, Thomas W.

AU - Vlachojannis, Georgios

AU - Arkenbout, Karin E.

AU - Holmvang, Lene

AU - Janssens, Luc

AU - Ochala, Andrzej

AU - Brugaletta, Salvatore

AU - Naber, Christoph K.

AU - Anderson, Richard

AU - Rittger, Harald

AU - Berti, Sergio

AU - Barbato, Emanuele

AU - Toth, Gabor G.

AU - Maillard, Luc

AU - Valina, Christian

AU - Buszman, Paweł

AU - Thiele, Holge

AU - Schächinger, Volker

AU - Lansky, Alexandra

AU - Wijns, William

PY - 2019

Y1 - 2019

N2 - Objectives: The aim of this study was to assess the 2-year clinical outcomes of the Firehawk stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel abluminal groove–filled biodegradable-polymer sirolimus-eluting coronary stent, compared with XIENCE (Abbott Vascular, Santa Clara, California), a durable-polymer everolimus-eluting coronary stent. Background: The long-term outcomes of the Firehawk stent have not been evaluated beyond 1 year in a randomized all-comers clinical trial. Methods: The TARGET All Comers study is a prospective, multicenter, all-comers, randomized, noninferiority trial conducted in Europe. A total of 1,653 patients were randomly assigned to undergo implantation of either the Firehawk or the XIENCE stent. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. Results: At 2-year follow-up, the incidence of target lesion failure was 8.7% in the Firehawk group versus 8.6% in the XIENCE group (p = 0.92). The event rates of individual components of the primary endpoint were comparable for the 2 groups. Landmark analyses between 1- and 2-year follow-up revealed no statistically significant difference of TLF for the Firehawk versus the XIENCE stent. Beyond 1 year, very late definite or probable stent thrombosis occurred in 3 patients (0.4%) in the Firehawk group and in 7 patients (0.9%) in the XIENCE group (p = 0.34). Conclusions: The 2-year follow-up of the TARGET All Comers study confirms comparable safety and efficacy profiles of the Firehawk and XIENCE stents.

AB - Objectives: The aim of this study was to assess the 2-year clinical outcomes of the Firehawk stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel abluminal groove–filled biodegradable-polymer sirolimus-eluting coronary stent, compared with XIENCE (Abbott Vascular, Santa Clara, California), a durable-polymer everolimus-eluting coronary stent. Background: The long-term outcomes of the Firehawk stent have not been evaluated beyond 1 year in a randomized all-comers clinical trial. Methods: The TARGET All Comers study is a prospective, multicenter, all-comers, randomized, noninferiority trial conducted in Europe. A total of 1,653 patients were randomly assigned to undergo implantation of either the Firehawk or the XIENCE stent. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. Results: At 2-year follow-up, the incidence of target lesion failure was 8.7% in the Firehawk group versus 8.6% in the XIENCE group (p = 0.92). The event rates of individual components of the primary endpoint were comparable for the 2 groups. Landmark analyses between 1- and 2-year follow-up revealed no statistically significant difference of TLF for the Firehawk versus the XIENCE stent. Beyond 1 year, very late definite or probable stent thrombosis occurred in 3 patients (0.4%) in the Firehawk group and in 7 patients (0.9%) in the XIENCE group (p = 0.34). Conclusions: The 2-year follow-up of the TARGET All Comers study confirms comparable safety and efficacy profiles of the Firehawk and XIENCE stents.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85071232609&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31129092

U2 - 10.1016/j.jcin.2019.05.001

DO - 10.1016/j.jcin.2019.05.001

M3 - Article

VL - 12

SP - 1679

EP - 1687

JO - JACC Cardiovascular Interventions

JF - JACC Cardiovascular Interventions

SN - 1936-8798

IS - 17

ER -